Bulimia Nervosa Treatment Market
- 2026 年市場規模
- USD 644.8 Mn
- 2033 年預估規模
- USD 964.6 Mn
- 年複合成長率 CAGR
- 5.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Bulimia Nervosa Treatment Market, By Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Benzodiazepines,Tricyclic Antidepressants, and Others) and Non-drug Treatment (Nutritional Therapy, Behavioral Therapy, and Others)), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.
Market Dynamics
Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.
Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.
Key features of the study
• This report provides an in-depth analysis of global bulimia nervosa treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global bulimia nervosa treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market
Market Segmentation
• By Treatment Type (Revenue, USD Mn, 2021-2033)
o Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
o Non-drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
• By Route of Administration (Revenue, USD Mn, 2021-2033)
o Oral
o Intravenous
o Others
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Bulimia Nervosa Treatment Market, By Region: (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Allergan, Inc.
o Eli Lilly and Company
o AstraZeneca plc
o Alembic Pharmaceuticals Ltd
o Bristol-Myers Squibb Company
o GlaxoSmithKline plc
o Pfizer Inc.
o Johnson & Johnson Services, Inc.
o Reddy’s Laboratories Limited
o Lupin Pharmaceuticals, Inc.
o Aurobindo Pharma
o Zydus Cadila
o Apotex Inc.
o Teva Pharmaceutical Industries Ltd
o Sun Pharmaceutical Industries Ltd
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Treatment Type
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Epidemiology
o Key Developments
o Regulatory Scenario
o PEST Analysis
o Product launches
o Acquisition and Merger Scenario
4. Global Bulimia Nervosa Treatment Market, By Treatment Type, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026, and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Drug Treatment
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Selective Serotonin Reuptake Inhibitor (SSRI)
o Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
o Benzodiazepines
o Tricyclic Antidepressants
o Others
o Non-drug Treatment
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Nutritional Therapy
o Behavioral Therapy
o Others
5. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026, and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Oral
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Intravenous
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Others
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
6. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, 2026, and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospital Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Retail Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Online Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
7. Global Bulimia Nervosa Treatment Market, By Region, 2021-2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2022 - 2033
o North America
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Company Profiles
Allergan, Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Eli Lilly and Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
AstraZeneca plc
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Alembic Pharmaceuticals Ltd
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Bristol-Myers Squibb Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
GlaxoSmithKline plc
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Pfizer Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Johnson & Johnson Services, Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Reddy’s Laboratories Limited
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Lupin Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Aurobindo Pharma
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Zydus Cadila
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Apotex Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Teva Pharmaceutical Industries Ltd
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Sun Pharmaceutical Industries Ltd
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們